Denali Therapeutics Stock Filter Stocks by Fundamentals
| DNLI Stock | USD 24.22 0.20 0.82% |
Denali Therapeutics fundamentals help investors to digest information that contributes to Denali Therapeutics' financial success or failures. It also enables traders to predict the movement of Denali Stock. The fundamental analysis module provides a way to measure Denali Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Denali Therapeutics stock.
Denali | Shares Owned by Institutions |
Denali Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Denali Therapeutics from analyzing Denali Therapeutics' financial statements. These drivers represent accounts that assess Denali Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Denali Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.9B | 1.7B | 9.1B | 3.5B | 2.9B | 2.2B | |
| Enterprise Value | 1.8B | 1.7B | 8.7B | 3.3B | 2.9B | 2.1B |
Denali Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Denali Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Denali Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Denali Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Denali Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Denali Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Denali Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-06-30 | 3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 2.4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.3 M | Alliancebernstein L.p. | 2024-06-30 | 2 M | Camber Capital Management Llc | 2024-09-30 | 2 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.6 M | Bank Of New York Mellon Corp | 2024-06-30 | 1.5 M | Principal Financial Group Inc | 2024-09-30 | 1.2 M | Baillie Gifford & Co Limited. | 2024-09-30 | 13.3 M | Blackrock Inc | 2024-06-30 | 13.2 M |
Denali Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.73 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Shares Owned By Insiders | 9.63 % | ||||
| Shares Owned By Institutions | 90.58 % | ||||
| Number Of Shares Shorted | 7.43 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 3,339 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (250.27 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 9.17 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Short Ratio | 11.35 X | ||||
| Earnings Per Share | (2.76) X | ||||
| Target Price | 41.69 | ||||
| Number Of Employees | 390 | ||||
| Beta | 1.39 | ||||
| Market Capitalization | 3.49 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
| Net Asset | 1.15 B |
About Denali Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Denali Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Denali Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Denali Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Denali Therapeutics Piotroski F Score and Denali Therapeutics Altman Z Score analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.